Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities
Clinical trial NCT05104918 · UNKNOWN
Trial details
- NCT number
- NCT05104918
- Sponsor
- Scotmann Pharmaceuticals
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-01
- Primary completion
- 2022-04-01
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.